174 related articles for article (PubMed ID: 26352894)
21. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
[TBL] [Abstract][Full Text] [Related]
22. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
Albiges L; Escudier B
Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
[TBL] [Abstract][Full Text] [Related]
23. Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M; Berthold D
Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
[TBL] [Abstract][Full Text] [Related]
24. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
25. Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB; Pal SK; Quinn DI
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
[TBL] [Abstract][Full Text] [Related]
26. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.
Cavaliere C; D'Aniello C; Pepa CD; Pisconti S; Berretta M; Facchini G
Curr Cancer Drug Targets; 2018; 18(5):468-479. PubMed ID: 28183256
[TBL] [Abstract][Full Text] [Related]
27. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
28. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
29. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for non-clear-cell renal cell carcinoma.
David KA; Milowsky MI; Nanus DM
Clin Genitourin Cancer; 2006 Mar; 4(4):263-8. PubMed ID: 16729909
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatment of renal cell cancer: A comprehensive review.
Sánchez-Gastaldo A; Kempf E; González Del Alba A; Duran I
Cancer Treat Rev; 2017 Nov; 60():77-89. PubMed ID: 28898679
[TBL] [Abstract][Full Text] [Related]
32. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
33. Therapy for non-clear cell histologies in renal cancer.
Bitting RL; Madden J; Armstrong AJ
Curr Clin Pharmacol; 2011 Aug; 6(3):169-80. PubMed ID: 21861801
[TBL] [Abstract][Full Text] [Related]
34. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Leroy X; Edeline J; Rioux-Leclercq N
Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
[TBL] [Abstract][Full Text] [Related]
35. Recent developments in small molecule therapies for renal cell carcinoma.
Song M
Eur J Med Chem; 2017 Dec; 142():383-392. PubMed ID: 28844802
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Bukowski RM
Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
[TBL] [Abstract][Full Text] [Related]
37. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
Agarwala SS; Case S
Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
39. [Molecular targeted therapy for advanced renal cell carcinoma].
Kanayama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
[TBL] [Abstract][Full Text] [Related]
40. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]